Literature DB >> 19390189

Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.

Nevriye Gonullu1, Fadimana Catal, Omer Kucukbasmaci, Sinem Ozdemir, Muzeyyen Mamal Torun, Rahmiye Berkiten.   

Abstract

BACKGROUND: We compared the in vitro activities of tigecycline with those of other agents against 97 Streptococcus pneumoniae, 140 Haemophilus influenzae and 54 Moraxella catarrhalis strains isolated in two large university hospitals in Istanbul.
METHODS: For analysis, the agar dilution method was used.
RESULTS: For S. pneumoniae isolates, 32% were not susceptible to penicillin (28.9% intermediate and 3.1% resistant). Cefotaxime, telithromycin, moxifloxacin and linezolid were fully active. Tigecycline had a 90% minimum inhibitory concentration (MIC(90)) of 0.12 microg/ml. For H. influenzae, 8.57% were not susceptible to ampicillin, among which 8 possessed beta-lactamase (5.7%). Four (2.87%) H. influenzae isolates with beta-lactamase-negative and ampicillin-resistant phenotype were found. All isolates were susceptible to ceftriaxone, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin. MIC(90) for tigecycline was 0.5 microg/ml. Of 54 M. catarrhalis isolates, 88.9% possessed beta-lactamase. Tigecycline and fluoroquinolones were highly active (MIC(90) < or =0.12 microg/ml).
CONCLUSIONS: Linezolid, telithromycin, newer fluoroquinolones and tigecycline all have excellent in vitro activities against the 3 respiratory pathogens. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390189     DOI: 10.1159/000214144

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae.

Authors:  Leyla Sirekbasan; Nevriye Gönüllü; Serhat Sirekbasan; Mert Kuşkucu; Kenan Midilli
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

2.  In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis.

Authors:  Xiang Sun; Bo Zhang; Guangjian Xu; Junwen Chen; Yongpeng Shang; Zhiwei Lin; Zhijian Yu; Jinxin Zheng; Bing Bai
Journal:  Ann Lab Med       Date:  2021-05-01       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.